Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,064.00GBp
22 Nov 2017
Change (% chg)

-- (--)
Prev Close
1,064.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
985,013
52-wk High
2,346.00
52-wk Low
906.50

Chart for

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products... (more)

Overall

Beta: 1.37
Market Cap(Mil.): £2,530.93
Shares Outstanding(Mil.): 240.66
Dividend: 8.50
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.69 15.46
EPS (TTM): -- -- --
ROI: -- 15.18 11.85
ROE: -- 16.59 15.83

BRIEF-Hikma Pharmaceuticals acquires six products from Boehringer Ingelheim GmbH

* ‍HIKMA ACQUIRES PRODUCTS IN EUROPE FROM BOEHRINGER INGELHEIM​

Nov 14 2017

UPDATE 1-Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

Nov 9 Hikma Pharmaceuticals Plc is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

Nov 09 2017

Drugmaker Hikma cuts generics sales forecast a third time

Nov 9 Hikma Pharmaceuticals Plc on Thursday lowered 2017 revenue guidance for its generics business for a third time.

Nov 09 2017

BRIEF-Hikma Pharmaceuticals says ‍continue to expect FY revenue around $2.0 bln​

* ‍CONTINUE TO EXPECT FULL YEAR REVENUE TO BE AROUND $2.0 BILLION IN CONSTANT CURRENCY IN 2017​

Nov 09 2017

BRIEF-Hikma launches serious infections treatment in the United States

* ‍CAPSULES ARE INDICATED FOR TREATMENT OF SERIOUS INFECTIONS CAUSED BY SUSCEPTIBLE STRAINS OF CANDIDA AND/OR CRYPTOCOCCUS​ Source text for Eikon: Further company coverage:

Nov 03 2017

BRIEF-Hikma says US unit launched pantoprazole sodium for injection

* U.S. unit west-ward pharmaceuticals has launched pantoprazole sodium for injection, 40mg​ Source text for Eikon: Further company coverage:

Oct 30 2017

Drugmaker Hikma's U.S. unit raises medicine prices: Financial Times

NEW YORK Hikma Pharmaceuticals Plc's U.S. subsidiary has raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines as well, the Financial Times reported on Sunday.

Aug 20 2017

Drugmaker Hikma's U.S. unit raises medicine prices -Financial Times

NEW YORK, Aug 20 Hikma Pharmaceuticals Plc's U.S. subsidiary has raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines as well, the Financial Times reported on Sunday.

Aug 20 2017

Drugmaker Hikma trims sales forecasts, shares fall

Hikma Pharmaceuticals Plc on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low.

Aug 17 2017

UPDATE 2-Drugmaker Hikma trims sales forecasts, shares fall

Aug 17 Hikma Pharmaceuticals Plc on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low.

Aug 17 2017

Earnings vs. Estimates